Apontis Pharma provides earnings guidance for the full year 2023. The company expects sales of EUR 36.1 million.
Market Closed -
Other stock markets
|
Pre-market 01:32:01 am | |||
8.98 EUR | -1.32% | 9.04 | +0.67% |
Apr. 05 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
Mar. 28 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+89.05% | 80.24M | |
+48.53% | 780B | |
+40.67% | 627B | |
-6.37% | 353B | |
+20.93% | 334B | |
+8.21% | 296B | |
+16.75% | 244B | |
-1.19% | 217B | |
+10.85% | 214B | |
+4.40% | 161B |
- Stock Market
- Equities
- APPH Stock
- News Apontis Pharma AG
- Apontis Pharma Provides Earnings Guidance for the Full Year 2023